Real-World Utilization of Molnupiravir during the COVID-19 Omicron Surge in Israel
Molnupiravir (MOV) was introduced in Israel in January 2022 during the SARS-CoV-2 Omicron surge for high-risk patients contraindicated for nirmatrelvir/ritonavir. This retrospective cohort study aimed to describe characteristics of patients offered COVID-19 antiviral treatment in Maccabi Healthcare...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-08-01
|
| Series: | Epidemiologia |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2673-3986/4/3/31 |